ArticleDiscover oncology2025
Comprehensive analysis of SELPLG as a potential immunotherapy target and prognostic biomarker in oncology.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSELPLG, which encodes P-selectin glycoprotein ligand-1, has emerged as a potential oncological target. A comprehensive understanding of its expression patterns across various cancer types and stages is crucial for elucidating its prognostic, therapeutic, and immunological roles.
methodsWe conducted an extensive bioinformatics analysis using multiple computational tools. TIMER2 was employed to quantify SELPLG mRNA expression in both tumor and normal tissues across diverse cancer types. Expression differences were further analyzed across clinical TNM stages and T stages. To investigate SELPLG expression at cellular and subcellular levels, we integrated genetic localization and single-cell sequencing data. A pan-cancer mutational landscape analysis was performed using Sangerbox 3.0. The prognostic significance of SELPLG expression was assessed using Cox proportional hazards regression models. Gene set enrichment analysis (GSEA) identified SELPLG-associated signaling pathways, while correlation analyses examined its relationship with immune cell infiltration.
resultsSELPLG was significantly upregulated in multiple tumor types, including breast (BRCA), cholangiocarcinoma (CHOL), esophageal (ESCA), head and neck (HNSC), kidney chromophobe (KICH), kidney renal papillary carcinoma (KIRP), stomach (STAD), and thyroid (THCA) cancers. Conversely, it was downregulated in lung adenocarcinoma (LUAD), colon (COAD), lung squamous cell carcinoma (LUSC), and bladder (BLCA) cancers. Differential expression analyses reinforced these findings across various cancer types and stages. Genetic localization studies revealed predominant SELPLG expression in lymphoid and myeloid cells, while single-cell sequencing data indicated enrichment in immune cell populations. The mutational landscape analysis identified frequent missense mutations across cancers. Prognostic analyses confirmed significant associations between SELPLG expression and patient outcomes. GSEA indicated SELPLG's involvement in immune-related pathways, and correlation analyses established a positive association between SELPLG expression and immunomodulatory factors.
conclusionsThis comprehensive study supports SELPLG as a promising prognostic, therapeutic, and immunological biomarker in cancer. Our findings underscore its role in tumor progression, immune response modulation, and potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.